The XXI century saw the introduction and spread of emerging potentially pandemic dangerous
infectious diseases, such as novel coronaviruses and a number of avian influenza viruses. 20 years
ago, the first laboratory-confirmed case of human infection with an avian influenza H5N1 was
recognized. The wide enzootic spread of highly pathogenic H5N1 virus among wild and domestic
poultry and a number of severe human respiratory diseases caused by the H5N1 virus have
stimulated the urgent necessity of development of potentially pandemic influenza vaccines.
Live, attenuated cold-adapted reassortant influenza vaccine (LAIV) is considered by World
Health Organization as one of the most promising preparations for preventing pandemics. LAIV has
proven to be safe and efficacious; pandemic LAIV might be more effective than an inactivated
vaccine in providing a broader immune response. This chapter described the development of
LAIVs against potential pandemic H5N1 subtype avian influenza viruses based on Russian
cold-adapted master donor virus, A/Leningrad/134/17/57 (H2N2), and their preclinical and clinical

Author(s) Details

Irina Kiseleva
Institute of Experimental Medicine, Saint Petersburg, Russia and Saint Petersburg State University, Saint Petersburg, Russia.

Natalie Larionova
Institute of Experimental Medicine, Saint Petersburg, Russia.

View Book :-

Spread the love

Leave A Comment

Recent Comments

No comments to show.